Study Summary
This trial is testing a new cancer drug (selumetinib) to see if it is safe when combined with the standard dose of another cancer drug (azacitidine). The study will last about 24 months, and patients will be taken off the study if they experience disease progression, unacceptable toxicity, or other illnesses.
- Myelofibrosis
- Leukemia
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: From the start of treatment to the date of death, not to exceed 100 months, whichever comes first.
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
Azacitidine and selumetinib
1 of 1
Experimental Treatment
18 Total Participants · 1 Treatment Group
Primary Treatment: Selumetinib · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What indications are Selumetinib normally prescribed to treat?
"Selumetinib is commonly prescribed as an induction chemotherapy and also to address cases of refractory anemias, leukemia, myelocytic, acute, multilineage dysplasia." - Anonymous Online Contributor
Are there currently enrollees to this research experiment?
"Affirmative. The data hosted on clinicaltrials.gov affirms that this research endeavour is actively looking for participants, with the original posting having been made on September 4th 2018 and a recent update occurring on May 16th 2022. 18 individuals are desired from one medical centre." - Anonymous Online Contributor
What is the current enrollment size for this trial?
"Affirmative. The information hosted on clinicaltrials.gov demonstrates that this research project, which was first announced on September 4th 2018, is currently accepting participants. 18 individuals need to be sourced from a single medical site in total." - Anonymous Online Contributor
Is there a corpus of literature analyzing the effects of Selumetinib?
"At present, 207 clinical studies are examining Selumetinib. Of these investigations, 37 have progressed to Phase 3. The majority of research is conducted in Saint Louis, Missouri; however other trial sites can be found across the country with a total of 6675 locations offering this treatment." - Anonymous Online Contributor
Has Selumetinib received clearance from the Food and Drug Administration?
"As this is a Phase 1 trial, the safety of Selumetinib has been preliminarily assessed and assigned a score of 1. This rating reflects the limited data available concerning efficacy and safety." - Anonymous Online Contributor